{
    "title": "U.S. FDA greenlights Provention Bio's diabetes drug",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11441785/U-S-FDA-greenlights-Provention-Bios-diabetes-drug.html",
    "date": "2022-11-17",
    "keywords": [
        "drug",
        "provention",
        "type",
        "insulin",
        "bhanvi",
        "satija",
        "bio",
        "onset",
        "disease",
        "blood",
        "sugar",
        "sanofi",
        "deal",
        "thursday",
        "food",
        "administration",
        "use",
        "teplizumab",
        "treatment",
        "health",
        "regulator",
        "brand",
        "name",
        "tzield",
        "abnormality",
        "stability",
        "channel",
        "end",
        "year",
        "jason",
        "hoitt",
        "officer",
        "partner",
        "launch",
        "copromotion",
        "drugmaker",
        "negotiation",
        "exchange",
        "payment",
        "value",
        "indication",
        "hope",
        "collaboration",
        "future",
        "bogillot",
        "head",
        "approval",
        "stock",
        "standard",
        "care",
        "antibody",
        "bodys",
        "response",
        "thereby",
        "juvenile",
        "immune",
        "system",
        "beta",
        "reporting",
        "srinivasan",
        "bengaluru",
        "editing",
        "vinay",
        "dwivedi",
        "maju",
        "samuel"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}